Edition:
United States

MyoKardia Inc (MYOK.OQ)

MYOK.OQ on NASDAQ Stock Exchange Global Select Market

58.25USD
21 Feb 2018
Change (% chg)

-- (--)
Prev Close
$58.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
114,103
52-wk High
$59.10
52-wk Low
$10.85

Chart for

About

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializi... (more)

Overall

Beta: --
Market Cap(Mil.): $2,081.92
Shares Outstanding(Mil.): 35.74
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 187.16 16.73
EPS (TTM): -- -- --
ROI: -- -0.71 35.60
ROE: -- -3.52 17.23

BRIEF-Myokardia Begins Patient Dosing In Phase 1B Clinical Study Of Myk-491

* MYOKARDIA BEGINS PATIENT DOSING IN PHASE 1B CLINICAL STUDY OF MYK-491 IN DILATED CARDIOMYOPATHY PATIENTS

Feb 14 2018

BRIEF-MyoKardia Inc reports Q3 loss per share $0.42

* MyoKardia Inc reports third quarter 2017 financial results and operational progress

Nov 02 2017

BRIEF-MyoKardia expects to initiate next trial of MYK-491 in DCM patients by year-end

* MyoKardia Inc - ‍next trial of MYK-491 in DCM patients expected to initiate by year-end​

Sep 27 2017

Earnings vs. Estimates